IndustryCompany release

Zymeworks raises 2026 guidance after Ziihera first-line approval and $250M Jazz milestone

🇺🇸 Zymeworks Inc. (ZYME) · Mon 09 Nov 2026

The company now expects 2026 revenue of $337–351 million and adjusted EBITDA of $176–190 million, citing the Jazz milestone, the Theravance acquisition and the Roche ZW209 licence.

Zymeworks reported its third-quarter 2026 results on 9 November and raised its full-year financial guidance. It now expects total revenue of $337–351 million and adjusted EBITDA of $176–190 million.

The company links the increase to a $250 million milestone payment from Jazz. The payment followed US Food and Drug Administration approval of Ziihera (zanidatamab-hrii) for first-line treatment of HER2-positive advanced gastroesophageal adenocarcinoma.

The revised outlook also reflects the completed acquisition of Theravance Biopharma, which brings YUPELRI into the Zymeworks business. A further factor is the licence of ZW209 to Roche. That deal still awaits clearance under the Hart-Scott-Rodino (HSR) Act, the US antitrust pre-merger review regime.

The full text of the results announcement was not available to VigiEye. This report is therefore based on the company's summary of the figures and drivers.

What it means for your team

  • The first-line gastroesophageal adenocarcinoma approval for Ziihera is a commercial and regulatory milestone for HER2-positive disease, and the Jazz payment shows its financial weight for Zymeworks.
  • Market-access teams should note that the first-line setting may widen the eligible patient population. The source gives no detail on pricing or reimbursement.
  • The Roche ZW209 licence is not yet finalised, as it still awaits HSR clearance, so its contribution to guidance carries that regulatory condition.

Company's press release (SEC filing): Zymeworks Inc. ↗

Article written by VigiEye from the official source (Zymeworks Inc.). Claims are the company's own. AI-assisted; check the source before acting.

More Industry All →